Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.
A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.
Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Patients with highly transfusion dependent, relapsed/refractory myelodysplastic syndrome appear to have long-lasting transfusion independence and increased hemoglobin following treatment with imetelstat.
Tucatinib plus trastuzumab represents a valuable, novel option for HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer that is chemotherapy refractory, according to the authors of the phase 2 MOUNTAINEER trial.
The Molecular International Prognostic Scoring System appears to improve prognostic discrimination across all clinical end points compared with other scores in patients with myelodysplastic syndromes.
Simple hysterectomy may become the new standard of care for patients with low-risk, early-stage cervical cancer, according to an expert from Université Laval in Quebec City, Canada.
Results from the phase 3 NATALEE trial investigating ribociclib plus endocrine therapy may change practice for the treatment of hormone receptor–positive or HER2-negative early breast cancer, according to an expert from the University of Chicago Medicine.
The association between use of a telegenetics service and lower likelihood of germline testing was statistically significant among black veterans with cancer, according to a recent retrospective cohort study.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Data from a retrospective cohort study indicate that nearly all patients receiving chemotherapy for small cell lung cancer in the community setting appear to experience myelosuppressive toxicities.
Zanubrutinib appears to produce significantly better progression-free survival and overall cardiac safety compared with ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone following the combination’s approval by the FDA.
Data from a cohort study suggest MGMT promoter methylation could serve as a stratification factor for patients with low-grade and anaplastic gliomas harboring IDH–wild-type or IDH-mutant and co-deleted tumors.
The safety review committee of the phase 1/2 Acclaim-1 trial identifies a recommended phase 2 dose of quaratusugene ozeplasmid plus osimertinib in the management of advanced non–small cell lung cancer.
Data from the phase 3 CheckMate 816 trial support the European Medicines Agency’s Committee for Medicinal Products for Human Use recommendation to approve nivolumab plus platinum-based chemotherapy as a treatment for resectable non–small cell lung cancer.
Fifteen-year follow-up data suggest the importance of considering the trade-offs between risks and benefits of active monitoring, prostatectomy, and radiotherapy for localized prostate cancer.
The FDA sets a Prescription Drug User Fee Act date of November 25, 2023 for lifileucel in the treatment of patients with advanced melanoma.
Findings from the registrational phase 1/2 TRIDENT-1 trial support the new drug application for repotrectinib in the treatment of those with ROS1-positive advanced or metastatic non–small cell lung cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
18F-rhPSMA-7.3 injection is now available to help identify PSMA-positive lesions during PET imaging for patients with metastatic or recurrent prostate cancer.
Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.
Ropeginterferon alfa-2b-njft has been moved to preferred status in the National Comprehensive Cancer Network guidelines for polycythemia vera based on data supporting the agent’s superior efficacy and safety in high- and low-risk populations.
Findings from the phase 3 DAWNA-2 trial suggest that dalpiciclib plus endocrine therapy may be a potential novel first-line treatment option for hormone receptor–positive, HER2-negative advanced breast cancer.
Patients under the age of 3 with neuroblastoma experienced no significant negative impact on survival when their disease was reclassified from high-risk to intermediate-risk and their therapy was thusly reduced.
Synchronous disease appears to have a more hormone dependent transcriptional profile than metachronous disease, according to a retrospective review of patients with metastatic castration-sensitive prostate cancer.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Axicabtagene ciloleucel may prolong survival and improve outcomes vs standard-of-care therapy in older patients with relapsed/refractory large B-cell lymphoma.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
